drugset
drugset / Trial / NCT00375791

Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma

NCT00375791 ↗

Phase 2 Completed 67 enrolled AEterna Zentaris
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a phase 2 study of perifosine in patients with multiple myeloma. Patients will receive perifosine 150 mg at bedtime (qhs) daily. Patients will be assessed by serum and/or urine-electrophoresis at least every 3 weeks.

Timeline

Start
2005-12
Primary completion
2010-12
Completion
2011-10

Publications

  • Results Blood (ASH Annual Meeting Abstracts) 2007 110: Abstract 1164 © 2007 American Society of Hematology

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 20 mg Oral
Subject Perifosine Small molecule 150 mg Oral

Indications

plasma cell myeloma